CVA 21

Drug Profile

CVA 21

Alternative Names: Cavatak; Coxsackievirus A21; CVA-21

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViroTarg
  • Developer Merck & Co; Olivia Newton-John Cancer Research Institute; Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Bladder cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer
  • Suspended Head and neck cancer
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Glioma; Mesothelioma; Multiple myeloma; Pancreatic cancer

Most Recent Events

  • 09 Aug 2017 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in Australia (IV) (NCT02824965)
  • 02 Jun 2017 Updated efficacy and adverse events data from the phase Ib MITCI trial in Malignant melanoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Updated adverse events data from the phase I STORM/KEYNOTE-200 trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top